Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 7;11(7):1928.
doi: 10.3390/biomedicines11071928.

Significance of Diabetic Kidney Disease Biomarkers in Predicting Metabolic-Associated Fatty Liver Disease

Jaehyun Bae  1 , Byung-Wan Lee  2
Affiliations
Review

Significance of Diabetic Kidney Disease Biomarkers in Predicting Metabolic-Associated Fatty Liver Disease

Jaehyun Bae et al. Biomedicines. .

Abstract

Metabolic-associated fatty liver disease (MAFLD) and diabetic kidney disease (DKD) share various pathophysiological factors, and epidemiological evidence suggests that these two diseases are associated. Albuminuria and the estimated glomerular filtration rate, which are conventional biomarkers of DKD, are reportedly associated with the risk or severity of MAFLD. Recently, novel DKD biomarkers reflecting renal tubular injury have been introduced to complement conventional DKD markers. In this article, we looked at previous studies that showed an association between MAFLD and DKD, and also reviewed the significance of DKD biomarkers as predictive risk factors for MAFLD.

Keywords: biomarker; diabetic kidney disease; metabolic-associated fatty liver disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic diagram of common pathogenic mechanisms between MAFLD and DKD. Abbreviations: FFA, free fatty acid; DNL, de novo lipogenesis; AGE, advanced glycation end product; ROS, reactive oxygen species; RAS, renin-angiotensin system.
See this image and copyright information in PMC

References

    1. Diehl A.M., Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N. Engl. J. Med. 2017;377:2063–2072. doi: 10.1056/NEJMra1503519. - DOI - PubMed
    1. Younossi Z.M., Golabi P., Paik J.M., Henry A., Van Dongen C., Henry L. The global epidemiology of nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash): A systematic review. Hepatology. 2023;77:1335–1347. doi: 10.1097/HEP.0000000000000004. - DOI - PMC - PubMed
    1. Lee Y.H., Cho Y., Lee B.W., Park C.Y., Lee D.H., Cha B.S., Rhee E.J. Nonalcoholic fatty liver disease in diabetes. Part i: Epidemiology and diagnosis. Diabetes Metab. J. 2019;43:31–45. doi: 10.4093/dmj.2019.0011. - DOI - PMC - PubMed
    1. Younossi Z.M., Golabi P., de Avila L., Paik J.M., Srishord M., Fukui N., Qiu Y., Burns L., Afendy A., Nader F. The global epidemiology of nafld and nash in patients with type 2 diabetes: A systematic review and meta-analysis. J. Hepatol. 2019;71:793–801. doi: 10.1016/j.jhep.2019.06.021. - DOI - PubMed
    1. Eslam M., Sanyal A.J., George J. Mafld: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014.e1991. doi: 10.1053/j.gastro.2019.11.312. - DOI - PubMed

LinkOut - more resources